CStone Says PD-L1 Meets Overall Survival Endpoint for NSCLC
publication date: Jan 19, 2022
Suzhou CStone Pharma announced a China Phase III trial of its PD-L1 (Cejemly®) met its overall survival endpoint as a first-line therapy for non-small cell lung cancer. The PD-L1, sugemalimab, was administered together with chemotherapy to patients with Stage IV NSCLC. In December, CStone was approved to launch the regimen in China for metastatic squamous and non-squamous NSCLC, based on progression-free survival data. In the US, EQRx owns rights to sugemalimab and plans to market it as a lower cost alternative to PD-1/PD-L1 drugs from big pharmas. More details....
Stock Symbol: (HK: 2616)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.